| Revenue Growth | Legacy revenue discontinued; $11 million expected from inventory/transition services next year. |
|---|---|
| Mgmt Confidence | High confidence in clinical team's 100+ years experience and regulatory strategy. |
| Margin Trends | Eliminated $32 million in annual commercial expenses; interest income reached $0.8 million. |
| Op. Leverage | Transitioned to lean R&D model; interest income covers current operating expenses. |
| Segment Growth | DMD program shows 5.4 percentage point improvement in ejection fraction (p=0.002). |
| New Clients | Strategic partnership with Apotex Health closed July 1st for $100 million. |
| Capex & Debt | Debt-free after $5.2 million credit line repayment; $22 million special dividend paid. |
| Regulatory | Pre-NDA meeting held; FDA granted rolling review for Ifetroban in DMD. |
| Commentary | Strategic pivot from commercial operations to high-value rare disease drug development. |
| New Launches | Planned NDA submission for Ifetroban (DMD); Phase 2 oncology follow-up study planned. |
Growth
Net income reached $77.8 million including transaction gains; cash grew to $80.6 million.
Outlook
Cash reserves projected to fund operations for over five years.
Risks
Zero analyst questions were asked; management's reliance on natural history data for NDA approval.
The company's earnings call, NASDAQ: CPIX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Cumberland Pharmaceuticals Inc: key numbers
- Share price
- $5.80Close, Nov 17
- Market cap
- $87M
- Shares outstanding
- 15MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cumberland Pharmaceuticals Inc
All →Cumberland Pharmaceuticals Clinical Trial Data
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.
- Term
- 12 months
Cumberland Pharmaceuticals Business Update
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.
Cumberland Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $77.8M
Cumberland Pharmaceuticals reported a significant net income of $77.8 million for the quarter ended September 30, 2026, primarily driven by an $81.1 million gain from the disposal of discontinued operations. Total revenue from continuing operations increased to $2.2 million, while the company declared a substantial cash dividend of $22.5 million during the period.
- Key figure
- Net income $77.8M
Cumberland Pharmaceuticals Financial Results
Cumberland Pharmaceuticals reported Q3 2026 financial results, its first full quarter as a development-focused company following the $100 million divestiture of its commercial brands to Apotex Health. The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) following a successful Phase 2 trial.
- Term
- Q3 2026
“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline. Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”
A.J. Kazimi, CEO of Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Clinical Trial Data
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.
- Counterparty
- FDA
Cumberland Pharmaceuticals Clinical Trial Data
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.